99
Participants
Start Date
April 8, 2019
Primary Completion Date
March 30, 2020
Study Completion Date
September 8, 2020
Methoxyflurane 3mL
As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
Charles V Keating Emergency and Trauma Centre, QEII, Halifax
Royal Victoria Regional Health Centre, Barrie
Markham Stouffville, Markham
St. Joseph's Healthcare, Welland
Centre Integre Universitaire De Sante Et De Service Sociaux (CIUSSS) Saguenay-Lac-Saint Jean, Chicoutimi
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park
Purdue Pharma, Canada
INDUSTRY